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Abstract
The risk of poor post-operative outcome and the benefits of surgical resection as a curative
therapy require careful assessment by the clinical care team for patients with primary and sec-
ondary liver cancer. Advances in surgical techniques have improved patient outcomes but
identifying which individual patients are at greatest risk of poor post-operative liver perfor-
mance remains a challenge. Here we report results from a multicentre observational clinical
trial (ClinicalTrials.gov NCT03213314) which aimed to inform personalised pre-operative risk
assessment in liver cancer surgery by evaluating liver health using quantitative multipara-
metric magnetic resonance imaging (MRI). We combined estimation of future liver remnant
(FLR) volume with corrected T1 (cT1) of the liver parenchyma as a representation of liver
health in 143 patients prior to treatment. Patients with an elevated preoperative liver cT1,
indicative of fibroinflammation, had a longer post-operative hospital stay compared to those
with a cT1 within the normal range (6.5 vs 5 days; p = 0.0053). A composite score combining
FLR and cT1 predicted poor liver performance in the 5 days immediately following surgery
(AUROC = 0.78). Furthermore, this composite score correlated with the regenerative perfor-
mance of the liver in the 3 months following resection. This study highlights the utility of quanti-
tative MRI for identifying patients at increased risk of poor post-operative liver performance
and a longer stay in hospital. This approach has the potential to inform the assessment of indi-
vidualised patient risk as part of the clinical decision-making process for liver cancer surgery.
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Liver resection for primary and secondary malignant tumours is a fundamental component of
the multimodal treatment of cancer [1, 2]. When an individual patient and multidisciplinary
surgical team is considering liver resection, a major challenge is knowing in advance whether
liver surgery will be survivable and how that individual’s liver will recover function after sur-
gery [3]. We term this future liver performance (FLP), and misjudging FLP can result in post-
surgical liver failure and death [4].
Future liver performance is a function of future liver remnant (FLR) volume, FLR function
and liver regenerative capacity. FLR volume is typically straightforward to calculate from rou-
tine pre-operative imaging with computed tomography (CT) or magnetic resonance imaging
(MRI) [5]. However, this requires substantial time input from specialised radiologists [5] using
dedicated software tools to accurately delineate the planned FLR.
Estimates of FLR function are based on clinical risk factors, with older age or presence of
liver disease, obesity [6] or diabetes mellitus/metabolic syndrome [7] all indicative of poor FLP
[8]. When combined with laboratory indices of liver synthetic function (e.g., serum albumin
concentration or prothrombin time), these risk factors give a reasonable estimate of FLP to an
experienced liver surgeon [8]. More objective direct estimates of hepatocellular function can
be obtained using 99mTc-mebrofenin scintigraphy [9], 13C-methacetin metabolism [10], or
indocyanine green (ICG) clearance [11]. However, these methods require tracer injection and
specialised detection devices and have not been widely adopted by most centres offering liver
resection, with the exception of ICG clearance in Asia [12]. Various blood-based composite
risk scores have been created to estimate survival after liver resection including the 50–50 cri-
teria of prothrombin time and bilirubin [13], peak bilirubin >7mg/dL [14] and the Hyder-
Pawlik [4] composite score of creatinine, bilirubin, INR and the Clavien-Dindo grade; these
scores are all calculated on measurements taken in the time recovering after surgery and are
less sensitive to mild morbidities where changes in clinical management may still be required.
Poor liver regenerative capacity is difficult to predict accurately and to detect pre-opera-
tively when interventions intended to increase the FLR volume (FLRV) such as portal vein
embolization [15] or combined portal and hepatic vein occlusion, fail to induce hypertrophy
[16]. For an otherwise normal healthy liver affected by cancer, a FLRV of at least 5 cm3 per kg
body weight, or 25% of pre-operative size is taken as a safe threshold below which an individ-
ual undergoing liver resection is generally considered to have an unacceptable risk of post-
operative liver failure. For livers with evidence of parenchymal disease (e.g., cirrhosis) a higher
threshold 40% is commonly used [17]. These thresholds have been derived from cohort studies
and are based on cumulative experience of patients undergoing liver resection and do not take
into account individual variations in liver health. Patients with very healthy livers could toler-
ate smaller FLRVs and conversely, post-operative liver failure can occur in patients with FLRV
above the usual thresholds, often unexpectedly. Furthermore, some patients receiving systemic
anti-cancer therapy may also develop hepatica injury, including chemotherapy-associated stea-
tohepatitis, further increasing the risks associated with liver resection [18]. There is therefore a
great and unmet need to develop a non-invasive imaging technology that can accurately and
reliably quantify FLP when used pre-operatively.
LiverMultiScan is a non-invasive quantitative multiparametric MRI (mpMRI) technology
[19] that has shown high diagnostic accuracy for liver fibroinflammation [20], steatosis and
haemosiderosis [21], as well as predicting liver-related outcomes [22] in patients with
chronic liver disease. It has also been demonstrated to be cost-effective in stratifying patients
with non-alcoholic fatty liver disease [23] and sensitive to changes in non-alcoholic steatohe-
patitis [24].
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The aim of this study was to evaluate, for the first time, the utility of combining these quan-
titative mpMRI metrics of pre-operative liver health with estimated FLR to forecast individual-
ised risk of poor liver performance in patients undergoing surgical resection for cancer in the
liver.
Methods
This study was conducted in accordance with the principles of the Declaration of Helsinki
2013 and approved by the institutional research departments, the South East Scotland
Research Ethics Committee 02 (Reference: 17/SS/0049), NHS Scotland R&D and NHS
England HRA. The study was registered prospectively on www.clinicaltrials.gov
(NCT03213314) and the study design published [25]. Patients being considered for liver resec-
tion for cancer were recruited between 7th September 2017 and 31st January 2019 at The Royal
Infirmary of Edinburgh or Hampshire Hospitals NHS Foundation Trust with the last patient
to enter the study completing the protocol on 31st March 2019. There was no change in treat-
ment, intervention or randomisation in the study. Study data were collected and managed
using REDCap electronic data capture tools hosted at the Edinburgh Clinical Trials Unit
[26, 27].
Study assessments
In this observational clinical trial, patients were recruited following clinical diagnosis and
treatment planning. 419 individuals were identified at the multidisciplinary cancer meeting
and screened, 305 people were approached to take part, of whom 149 participated in the study
requiring a pre-operative and a 3-month post-operative study visit at an imaging centre. Rele-
vant clinical data were obtained by trained members of the Clinical Research Facility at each
site. Peripheral venous blood samples were obtained from each study participant on each visit
and at the time of surgery for multiple routine laboratory analyses and specialist assays. MR
images were acquired a mean of 3 days before surgery and 102 days following surgery at either
the Candover Clinic Hampshire Hospitals NHS Foundation Trust on a Siemens Aera 1.5T or
at the Queen’s Medical Research Institute, The University of Edinburgh on a Siemens Skyra
3T MRI scanner. Appropriate 3-plane localiser images were acquired of the abdomen and
mpMRI data were collected using non-contrast enhanced multi-slice acquisition protocols
along with a 3D image of the liver, totalling approximately 18 minutes.
Clinical care teams were blinded to research MRI scan reports and surgical procedures
were performed as standard of care with operative information collected as described in the
eCRF including details of the performed operation. Tissue samples were taken from liver
resection specimens with strict care being taken not to compromise the direct clinical care
pathology reporting. Fresh Tru-cut biopsies of the tumour and a 1 cm3 wedge biopsy of the
non-lesion liver parenchyma were snap frozen in liquid nitrogen in the operating theatre
immediately after the resection specimen was removed from the patient. Formalin-fixed paraf-
fin-embedded blocks of background liver and tumour tissue were obtained specifically for the
study at the time of specimen processing for direct clinical care pathology reporting using the
NAFLD activity score (NAS) [28], a summation of the semi-quantitative histological scores for
liver fat, inflammation and ballooning. The ISHAK score was used to assess fibrosis [29].
Image analysis
The Liver volume was delineated from three-dimensional T1-weighted VIBE images using a
semi-automatic approach, comprising an automatic deep learning based initialisation followed
by manual editing. The deep learning approach used a 3D U-net architecture as previously
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described [30]. Six cases were omitted as more than 5% of the liver volume was outside of the
field of view of the image acquisition. Tumour locations were defined and guided by the surgi-
cal notes and were manually delineated using ITK-SNAP [31] by tracing the tumour in three
orthogonal planes and interpolating into a 3D consolidated segmentation. Finally, the delin-
eated liver volume was subdivided into the anatomical Couinaud segments [32], based on
manually-placed 3D landmarks (inferior/superior vena cava, right/middle/left hepatic veins,
gall bladder fossa, umbilical fissure, left/right portal vein) following the guidelines of Germain
et al [33], to facilitate modelling of the planned segmentectomy planes. For atypical wedge
resections, a conical frustrum was modelled based on the tumour delineation and the resection
path from the liver surface. Surgical notes from the operation plan were used to inform the
estimation of FLR volume by removing anatomical segments and wedges as calculated above
(Fig 1).
Multislice quantitative cT1, proton density fat fraction (PDFF) and T2� maps were gener-
ated using proprietary LiverMultiScan software (Perspectum, UK) as previously described
[21] with operators blinded to patient status. The quantitative MRI maps were overlaid onto
the Couinaud segmented volumetric images to allow characterisation of liver tissue in the
FLR.
Morbidity outcome
Post-operative mortality has previously been modelled by Hyder and Pawlik [4] by combining
three weighted blood scores (INR, creatinine, bilirubin) with the Clavien-Dindo score on the
third day following surgery, which predicted 90 day mortality following resection for liver
cancer. In our study, excellent long-term post-operative patient outcomes were achieved and
only five patients exhibited a Hyder-Pawlik score>9.0 (S1 Fig) indicating that this study was
underpowered to reach the primary endpoint. However, measures of liver dysfunction in the
immediate days following surgery from blood-derived biomarkers (INR, creatinine, bilirubin
with Hyder-Pawlik weightings) can serve as an alternative measure of morbidity. We mea-
sured and summed these blood-derived biomarkers for each of the five days following surgery
and devised the modified Hyder-Pawlik score, to evaluate the risk of morbidity directly after
the operation.
Statistical analysis
Interim analyses were planned in advance. Any errors in data entry were reviewed and cor-
rected with the Chief Investigator’s permission. When longitudinal blood sampling was
incomplete for the anticipated 5 days (owing to early discharge from hospital), bilirubin,
creatinine or INR value was imputed from the value of the previous day. The Hyder-Pawlik
score was calculated for each patient based on the values at day 3 post-surgery of bilirubin
(mg/dL), creatinine (mg/dL), INR and maximum Clavien-Dindo grade, weighted as previ-
ously described [4]. The composite biomarker was generated after a stepwise logistic regres-
sion using a modified Hyder-Pawlik score of over 22 as a discriminator and the optimal
weighed predictors were selected by Akaike’s information criterion. The Youden index identi-
fied the optimal receiver operating characteristic.
Results
Of the 149 patients enrolled in the study, 135 patients underwent liver resection, 7 had portal
vein embolization to induce hypertrophy of the FLR and two individuals had transarterial che-
moembolisation (Fig 2a). A range of surgical procedures were planned (Fig 2b) resulting in
a median [IQR] FLR of 83% [23%–95%]. Demographics and clinicopathologic data are
PLOS ONE Quantitative MRI predicts individual future liver performance after resection for cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0238568 December 2, 2020 4 / 15
described in Table 1. The large majority (n = 114, 84% of participants) had liver metastases
from colorectal cancer; the remainder had hepatocellular carcinoma (n = 6), cholangiocarci-
noma (n = 1) or other metastases (n = 14) including breast cancer metastasis and ovarian can-
cer metastasis. 73 patients had received systemic anticancer chemotherapy that was ended a
median of 56 days prior to surgery. 12 patients presented with a diagnosed underlying liver
disease. MpMRI was performed in all patients and 21% of individuals (29/135) had pre-opera-
tive liver cT1 values greater than the upper limit of normal (795 ms) defined for the general
population [34, 35].
Fig 1. (a) Image analysis pipeline. A 3D U-net was trained using hand labelled maps to delineate the liver on 3D T1-weighted images. The surgical
plans and anatomical segments of Couinaud are semi-automatically delineated by placing anatomical landmarks. Quantitative tissue characteristics
maps are overlaid onto the 3D liver rendering. Segmentectomies or wedge resections defined by the surgical plan are virtually performed to calculate
the future liver remnant. (b) Two case studies indicating the proposed utility in clinical decision making.
https://doi.org/10.1371/journal.pone.0238568.g001
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Pre-operative multiparametric MRI correlates with liver histology
Patients displayed a range of tumour and parenchymal liver cT1 values, six examples are
shown in Fig 3a–3f. The case shown in Fig 3c depicts a parenchymal cT1 within the normal
range [34], and histological analysis of liver tissue adjacent to the tumour explant (white box,
Fig 3g) appears typical of a healthy liver showing no inflammation, ballooning or steatosis.
The case shown in Fig 3f shows a parenchymal cT1 above the normal healthy range and the
associated histology (Fig 3h) indicates ballooned hepatocytes, infiltration of inflammatory cells
and grade 3 steatosis.
cT1 correlated with histopathological scoring of ballooning (Spearman’s rho = 0.279,
p = 0.001) and inflammation (Spearman’s rho = 0.276, p<0.001) and PDFF correlated with
Fig 2. Trial design. (a) CONSORT diagram indicating enrolment in the HepaT1ca trial. Median and [IQR] or number
and (%). (b) Venn diagram indicating the range of surgical procedures carried out.
https://doi.org/10.1371/journal.pone.0238568.g002
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steatosis (Spearman’s rho = 0.702, P<0.0001). cT1 was significantly elevated in patients with a
ballooning score of 2 (� P = 0.0057) or an inflammation score of 2 (�P = 0.011). PDFF showed
significant stepwise increases with increasing steatosis scores (��� P<0.001) (Fig 3i–3k).
Pre-operative multiparametric MRI correlates with length of stay
In the subset of patients where at least 10% of the liver volume was removed (n = 77), the
median length of stay for patients with pre-operative cT1 above the upper limit of normal
(�795ms) was 1.5 days longer than those presenting with cT1 within the normal range (Fig 4).
Other variables (presence of comorbidities, resection volume greater than 50%, preoperative
bilirubin level above normal (20 μmol/L), total lesion volume above 100ml, age over 60 years,
Table 1. Clinicopathologic data for patients enrolled on the HepaT1ca trial prior to treatment.
Patient data n = 143
Age, y, median [IQR] 64 [56–72]
Sex ratio (male to female) 97:46
Diagnosis, n (%)
Liver metastasis (colorectal primary) 114 (79.7)
Liver metastasis (other primary) 22 (15.3)
Hepatocellular carcinoma 6 (4.2)
Cholangiocarcinoma 1 (0.6)
Known liver disease, n (%)
Alcohol-related 1 (0.6)
NAFLD 4 (2.8)
Hepatitis B 0 (0)
Hepatitis C 0 (0)
Primary biliary cholangitis 2 (1.4)
Primary sclerosing cholangitis 0 (0)
Haemochromatosis 0 (0)
Autoimmune hepatitis 2 (1.4)
Cirrhosis 3 (2.1)







Pre-operative LFT, median [IQR]
Bilirubin (μmol/L) 10 [8–19]
Albumin (μmol/L) 39 [36–40]
AST (U/L) 26 [22–32]
ALT (U/L) 23 [18–35]
ALP (U/L) 92 [74–119]
GGT (U/L) 39 [26–73]
Pre-operative imaging derived metrics, median [IQR]
Planned FLR (%) 82.8 [61.0–94.6]
corrected T1 (ms) 722.5 [689.2–772.5]
PDFF (%) 3.9 [2.5–8.0]
https://doi.org/10.1371/journal.pone.0238568.t001
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BMI over 25 kg/m2, liver fat over 10%) all showed no significant difference (P>0.05) in length
of stay between groups.
Pre-operative multiparametric MRI predicts with post-operative morbidity
The primary endpoint of this study was to determine the ability of LiverMultiScan to predict
risk of post-operative morbidity and mortality by measuring the correlation between the pre-
operative liver health assessment score and the post-operative liver function composite inte-
ger-based risk (Hyder-Pawlik) score; the modified Hyder-Pawlik score (Fig 5a) was also evalu-
ated. Patients with high cT1 had a slightly elevated Hyder-Pawlik score at day 3 than patients
with a normal cT1 (P = 0.11 no significant difference), and had a significantly higher modified
Hyder-Pawlik score (Fig 5b) than patients with a normal cT1 (P = 0.0076).
Fig 3. (a-f) Quantitative MR images of the liver from six patients presenting with liver cancer using LiverMultiScan showing range of cT1 values found in the
parenchyma. (g,h) Haematoxylin & eosin stains of parenchymal tissue taken from explant of patient with colorectal liver metastasis (c, white box) showing healthy liver
tissue and a patient with hepatocellular carcinoma (f, white box) showing hepatocellular ballooning, clusters of inflammatory cells and regions of steatosis. (I, j, k)
Box and Whisker plots of preoperative cT1 or proton density fat fraction (PDFF) against histopathological scoring of ballooning, inflammation or steatosis in explant
tissue (1-way ANOVA with Tukey’s post-hoc test).
https://doi.org/10.1371/journal.pone.0238568.g003
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Stepwise logistic regression was performed on the following nine pre-operative variables to
determine the diagnostic accuracy to discriminate the patients with a 5-day sum of modified
Hyder-Pawlik scores in the upper quartile: age, BMI, creatinine, bilirubin, liver volume, lesion
volume, FLR, liver fat and liver cT1. The model was trained using a subset of data (n = 62) in
whom at least 10% of the liver volume was removed to exclude patients with very small resec-
tions and for whom complete data were available. Non-collinearity of predictors was con-
firmed using linear regression models. A combination of FLR and pre-operative cT1 had the
best performance with an AUROC of 0.78 (95% confidence intervals: 0.66, 0.90) (Fig 5c). The
resulting composite biomarker was termed the ‘Hepatica score’, with a lower FLR and a higher
pre-operative cT1 predictive of an increased risk of poor post-operative outcome. This com-
posite biomarker showed a significantly higher diagnostic performance (DeLong’s test for two
correlated ROC curves P = 0.000104) than FLR alone with an AUROC of 0.70 (95% CI 0.55–
0.84).
Hepatica score ¼ e  ð1:24þðlogFLR�   2:26ÞþðcT1� 0:013ÞÞ
Hepatica predicts liver regeneration
96 patients returned for a post-operative follow-up mpMRI scan at a mean of 102 ±4.7 days
after their operation. The volume of the liver at this timepoint was measured semi-automati-
cally as described above, with 42% of patients regenerating at least 90% of the resected liver
volume. The Hepatica score, measured pre-operatively, correlated with the achieved regenera-
tion (Fig 5d, R2 = 0.48, P<0.0001). One example of liver regeneration is depicted; the pre-oper-
ative mpMRI indicated a lesion on the right lobe of the liver (Fig 5e), with the resection plan
and FLR show in red (Fig 5f). The follow-up scan reveals left lobe hypertrophy (Fig 5g) with a
measured increase in total liver volume of 798mL (Fig 5h).
Discussion
This study aimed to augment current methods for estimating FLP by incorporating non-inva-
sive, contrast-agent free quantitative mpMRI to inform the risk assessment for patients indi-
cated for liver surgery for cancer in the liver. We have shown here that patients with pre-
Fig 4. Length of stay. Length of stay is 1.5 days longer if there is liver fibroinflammation measured by cT1 in patients
with a predicted FLR<90% (high cT1>795ms; Wilcoxon rank sum test ��P = 0.0053, n = 77).
https://doi.org/10.1371/journal.pone.0238568.g004
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Fig 5. Post-surgery outcomes. (a) The modified Hyder-Pawlik score measured before and at each day following
surgery (2.5�INR + 17.1�bilirubin + 88.4�creatinine). (b) Sum of the modified Hyder-Pawlik score over 5 days is
significantly higher in patients presenting with high preoperative liver cT1 (P = 0.0076). (c) Receiver operating
characteristic curve describing the diagnostic ability of the Hepatica score to discriminate the upper quartile of patients
representing those with a poor post-operative outcome. (d) Achieved regeneration score (calculated by dividing pre-
operative liver volume by the liver volume measured a median of 99 days following resection for liver cancer)
PLOS ONE Quantitative MRI predicts individual future liver performance after resection for cancer
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operative liver cT1, a biomarker of fibroinflammation, above the upper limit of normal spent
on average 1.5 days longer in hospital than those with cT1 in the normal range. Factors affect-
ing length of stay have been investigated previously for liver resection [36, 37] but this is the
first report of a non-invasive imaging approach identifying a patient group with a higher
length of stay. This is of particular importance given the significant healthcare costs associated
with in-patient care (~£10,000 total post-operative costs [38]). The correlations observed for
cT1 and PDFF with histological measures of ballooning, inflammation and steatosis in this
surgical population, reinforce previously published associations in patients with chronic liver
disease [19, 21]. Taken together, this evidence highlights a role for mpMRI in characterising
liver disease in place of an invasive liver biopsy, which is typically only performed in selected
patients with chronic liver disease as part of the pre-operative work-up, owing to the risk of
haemorrhage and tumour seeding [39, 40].
The primary endpoint in this study was to determine the correlation between a composite
of FLR and pre-operative liver cT1, with a measure of post-operative morbidity, the Hyder-
Pawlik score [4]. The weak correlation seen in this study (multiple R-squared = 0.14) is likely
due to low rate of substantial morbidity observed in comparison to that reported by Hyder
and colleagues [4]. As a result, our study was insufficiently powered to meet the primary end-
point. The low rate of morbidity is likely due to a combination of factors including liver cancer
indication; 18.2% of cases were reported to present with HCC by Hyder and colleagues, while
only 6 of 143 (4.2%) cases in our study presented with HCC. Additionally, 9.1% of cases inves-
tigated by Hyder and colleagues presented with underlying liver cirrhosis whereas no patients
in our study were found to have histological cirrhosis (modified ISHAK fibrosis score 6).
The Hyder-Pawlik score identifies an increased risk of 90-day mortality when measured as
>9 points at day 3 post-surgery. Prediction of 90-day mortality using patient information col-
lected after the surgical procedure has utility in enabling clinical decisions regarding the level
of post-operative care required for the patient. However, additional patient outcome and man-
agement benefits may be gained if such analysis was carried out pre-operatively. In this study,
we opted to investigate imaging-based pre-surgical variables that would permit the evaluation
of the risk of the surgical procedure before it was carried out. The composite biomarker
‘Hepatica score’ generated in our study performed well at classifying the quartile of patients
with poor liver function as measured on each of the five days following surgery (modified
Hyder-Pawlik score). We propose that this approach better captures the transient changes in
serum liver enzymes that are indicative of limited liver function [41] and are used in clinical
monitoring to guide changes in patient management during post-operative recovery.
Another key element in the recovery of patients following liver resection is the capacity
of the liver to regenerate. In this study, the pre-operative Hepatica score showed excellent cor-
relation with the volume of liver regenerated at the 3-month post-operative MRI scan. This
highlights the utility of augmenting FLR with a measure of liver health, in this case the fibroin-
flammatory biomarker, cT1. Our understanding of the processes regulating liver regeneration
are evolving, but inflammation [42] and recent chemotherapy prior to resection [43] have pre-
viously been reported as important modifiers.
A limitation of this study is the relatively small number of patients with poor post-operative
liver performance. In order to build suitably robust and transferable predictive models, a suffi-
ciently wide distribution of patients is required. As this study was prespecified to enrol all-
correlated with the pre-operative Hepatica score (R2 = 0.48). (e, f) Exemplar pre-surgical cT1 map and T1-weighted
image with FLR overlaid (red) of a patient presenting with a HCC lesion in the right lobe of the liver. (g, h) Post-
surgical cT1 map and T1 weighted image of the same patient 3 months following surgery.
https://doi.org/10.1371/journal.pone.0238568.g005
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comers at tertiary referral centres in the UK, the patients recruited reflected the relatively low
prevalence of primary liver cancer in this region with the majority having metastatic liver can-
cer on a background of relatively healthy liver tissue. A second limitation is our use of a new
measure of post-operative liver performance, the modified Hyder-Pawlik score. This approach
was derived to provide increased sensitivity to more subtle derangements in post-operative
liver function and to allow an understanding of the acute care requirements and level of obser-
vation required for patients still under the care of the surgeon and associated multidisciplinary
team. This scoring system and its clinical validity requires further evaluation in future studies.
In summary, the results presented in this study highlight the utility of pre-operative
mpMRI for predicting post-operative liver performance and associated length of stay in hospi-
tal. This has the potential to transform surgical decision-making and improve personalised
risk assessment for patients undergoing liver resection for cancer. Further evaluation of this
technology is needed to fully evaluate the clinical utility in a broader patient population.
Supporting information
S1 Fig. (a) Distribution of Hyder-Pawlik scores measured 3 days following surgery.
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